Una Health is pleased to announce a strategic new partnership with Credo Diagnostics, enabling the UK distribution of the VitaPCR™ rapid molecular testing platform. This collaboration brings fast, laboratory-grade respiratory virus detection directly to point-of-care settings across the UK.

Building on our mission to deliver cutting-edge point of care diagnostics, this agreement complements our portfolio of infectious diseases and respiratory health solutions.

What is VitaPCR™?

• Fast Real‑Time PCR: Utilises real-time RT‑PCR for detection of SARS-CoV‑2, Flu A&B and RSV, delivering test results in just 20 minutes— with accuracy comparable to laboratory methods
• Simple workflow: Single‑step lysis and extraction from oro- or nasopharyngeal swabs. Very little hands-on prep.
• No lab equipment required: Lightweight (1.2 kg), small footprint, and standalone operation
• CE‑marked and CTDA approved: Approved for clinical use, ensuring adherence to quality and regulatory standards.

Why this matters

• Rapid, accurate results at point-of-care: Ideal for wards and community settings where fast results are needed for effective triaging.
• Infection control: Swift identification of COVID‑19, influenza A/B and RSV reduces transmission and enables immediate patient management.
• Scalable solution: Its compact design allows deployment in virtually any setting, making it ideal for meeting increased testing demands during the winter season while complementing existing laboratory capacity.

This partnership represents a significant step forward in Una Health’s strategy to expand molecular diagnostic solutions at the point of care. It reinforces our commitment to equipping healthcare professionals with reliable diagnostics that support faster decision-making, improved patient outcomes, and greater system efficiency.

Don’t wait for winter pressures to build. Get ahead with cost effective, rapid point of care PCR testing—book your VitaPCR™ demo now.